Photo by © Susan Lloyd/Clemson Sports Talk
Clemson Football

Wes Goodwin on freshman DL Peter Woods: 'You just know he’s different'

March 13, 2023


TAKE ADVANTAGE → Become a CST+ Member for just $1.00


On heading into season two:

“I’d say the biggest thing is to do the little things better-- technique, fundamentals, presnap alignment, where to put our eyes, stances, assignments, and executing that at a high level. Schematically we’ve done a lot of good things. We’ve just got to do the little things better.”

On Clemson back seven:

“I knew there were going to be a lot of challenges last year. Me being in my first year, but replacing a lot of experience and a wealth of talent from the previous year in the back seven-- two all ACC corners and all of that crew. Those guys got a lot of exposure last year and got thrown in the fire. Obviously, the bowl game didn’t go as planned. Still, throughout the season, watching guys improve and mature in the backend on and off the field from an outside-in view, you may not see the progress, but being around these guys on a daily basis you could see the progress with all these guys.”

On freshman DL Peter Woods:

“He’s special. He’s one of those that rolls in-- I mean, you just know he’s different. He arrives, and he’s got the 4th or 5th most muscle mass on the team? His explosiveness? Some of these recruiting sites knock him for not being tall enough, but he’s very much tall enough. He’s an amazing man off the field. He’s a winner. Works extremely hard. He’s powerful-- explosive. He can play on the edge, he can play inside. He can play all the techniques upfront. He’s super heavy handed, explosive, violent, the list goes on and on.”

Watch the full interview with Coach Goodwin above.

Discussion from...

Wes Goodwin on freshman DL Peter Woods: 'You just know he’s different'

2,645 Views | 0 Replies | Last: 1 yr ago by Staff Reports
There are not any replies to this post yet.
Page 1 of 1
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.